2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Antibody Therapy, Transfusion, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

1202 Immune regulatory cell populations in patients with clonal and non-clonal chronic idiopathic neutropenia (CIN)

Nikoleta Bizymi, MD, MSc, PhD, Greg Tsaknakis, PhD2, Athina Damianaki3, Nikoletta Aresti, BSc, MSc4, Anastasios Karasachinidis, BSc, MSc5, Vasileia Kaliafentaki, MD, MSc6, Aristea Batsali, PhD7, Irene Mavroudi, PhD8, Maria Velegraki, MD, PhD9, Charalampos G Pontikoglou10, Helen Papadaki, MD, PhD11
1 Department of Hematology, University Hospital of Heraklion, Heraklion, Greece, Hemopoiesis Research Laboratory, University of Crete, School of Medicine, Heraklion, Greece
2 Department of Hematology, University Hospital of Heraklion, Heraklion, Greece, Hemopoiesis Research Laboratory, University of Crete, School of Medicine, Heraklion, Greece
3 Department of Hematology, University Hospital of Heraklion, Heraklion, Greece, Hemopoiesis Research Laboratory, University of Crete, School of Medicine, Heraklion, Greece
4 Department of Hematology, University Hospital of Heraklion, Heraklion, Greece, Hemopoiesis Research Laboratory, University of Crete, School of Medicine, Heraklion, Greece
5 Department of Hematology, University Hospital of Heraklion, Heraklion, Greece, Hemopoiesis Research Laboratory, University of Crete, School of Medicine, Heraklion, Greece
6 Department of Hematology, University Hospital of Heraklion, Heraklion, Greece, Hemopoiesis Research Laboratory, University of Crete, School of Medicine, Heraklion, Greece
7 Department of Hematology, University Hospital of Heraklion, Heraklion, Greece, Hemopoiesis Research Laboratory, University of Crete, School of Medicine, Heraklion, Greece
8 Department of Hematology, University Hospital of Heraklion, Heraklion, Greece, Hemopoiesis Research Laboratory, University of Crete, School of Medicine, Heraklion, Greece
9 Department of Hematology, University Hospital of Heraklion, Heraklion, Greece, Hemopoiesis Research Laboratory, University of Crete, School of Medicine, Heraklion, Greece
10 Department of Hematology, University Hospital of Heraklion, Heraklion, Greece, Hemopoiesis Research Laboratory, University of Crete, School of Medicine, Heraklion, Greece
11 Department of Hematology, University Hospital of Heraklion, Heraklion, Greece, Hemopoiesis Research Laboratory, University of Crete, School of Medicine, Heraklion, Greece

Introduction. Chronic idiopathic neutropenia (CIN) is a heterogeneous hematologic disorder characterized by persistent neutropenia in the absence of a secondary cause. A subset of CIN patients harbor clonal hematopoiesis (CH) - associated somatic mutations, which may affect the natural history of the disease and the risk of malignant transformation. Myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) are key immunosuppressive populations implicated in myeloid neoplasia, yet their characterization in clonal versus non-clonal CIN remains poorly defined.

We have previously demonstrated that MDSCs are significantly reduced in both peripheral blood (PB) and bone marrow (BM) of CIN patients compared to healthy controls (Bizymi et al, HemaSphere 2024), with preserved T-cell suppressive activity but an altered immunomodulatory transcriptome. Tregs were found significantly elevated in PB versus controls, with higher levels in PB than BM, consistent with peripheral induction as a compensatory response to activated oligoclonal T lymphocytes (Bizymi et al, EHA Congress 2026). Additionally, PB monocyte subsets are altered in CIN, with decreased classical and increased intermediate and non-classical monocytes, potentially amplifying the proinflammatory BM microenvironment (Bizymi et al, J Clin Immunol 2019).

Methods. PB MDSC data were analyzed in 102 CIN patients: 16 with CH (defined by NGS detection of somatic mutations in myeloid genes with a variant allele frequency ≥2%) and 86 with non-CH. MDSCs were quantified by flow cytometry as monocytic MDSCs (M-MDSCs; CD14+CD15−HLA-DRlow/-CD11b+CD33+), polymorphonuclear MDSCs (PMN-MDSCs; CD15+CD14−HLA-DRlow/-CD11b+CD33+), and total MDSCs (sum). PB Treg subpopulations were assessed in 39 patients (clonal n=7, non-clonal n=32), including CD4+CD25high %, FOXP3+ within CD4+CD25high %, CD4+CD25highFOXP3+ %, and absolute CD4+CD25high counts. Monocyte subsets were assessed by flow cytometry in 53 patients (clonal n=9, non-clonal n=44) and classified as classical (CD14++CD16−), intermediate (CD14++CD16+), and non-classical (CD14dimCD16+). Spearman correlation between MDSCs and Tregs was performed in 16 matched patients. Disease evolution (to acute myeloid leukemia [AML] or myelodysplastic syndrome/myeloproliferative neoplasm [MDS/MPN]) was compared between 3 evolving and 99 non-evolving patients. Group comparisons used two-sided Mann-Whitney U tests.

Results. PB MDSC levels did not differ significantly between clonal and non-clonal CIN patients (M-MDSCs: median 0.77% vs 0.98%, p=0.703; PMN-MDSCs: 0.39% vs 0.34%, p=0.843; total MDSCs: 1.33% vs 1.69%, p=0.385). Among PB Treg subpopulations, FOXP3+ expression within CD4+CD25high T cells was significantly higher in clonal compared to non-clonal patients (median 0.894% vs 0.853%, p=0.048), while CD4+CD25high %, CD4+CD25highFOXP3+ %, and absolute counts did not differ significantly. Spearman correlation analysis in the full CIN cohort revealed a significant positive association between PMN-MDSCs and CD4+CD25high Tregs (r=0.538, p=0.032). Subgroup analyses within clonal and non-clonal CIN patients separately did not reach significance, likely reflecting limited sample size. No significant differences in any MDSC subpopulation were observed between patients who evolved to myeloid malignancy and those with stable disease (M-MDSCs p=0.359; PMN-MDSCs p=0.911; total MDSCs p=0.309). Monocyte subset analysis (n=53) revealed no significant differences in classical, intermediate, or non-classical monocyte proportions between clonal and non-clonal CIN patients.

Conclusions. PB MDSC frequencies are comparable between clonal and non-clonal CIN patients, suggesting that CH does not broadly alter the myeloid suppressor cell compartment at this disease stage. However, clonal CIN is associated with elevated FOXP3 expression within CD4+CD25high Tregs, indicating qualitative differences in the Treg compartment that may reflect CH-driven immune modulation. The significant positive correlation between PMN-MDSCs and CD4+CD25high Tregs across the CIN cohort points to coordinated immunosuppressive mechanisms that operate independently of the presence of CH. Monocyte subset distribution was similarly unaffected. These findings provide novel insights into the immunoregulatory landscape of CIN and support prospective validation in larger cohorts with extended follow-up.

Nikoleta Bizymi, MD, MSc, PhD: No relevant conflicts of interest to declare.